pp-098 Gel

Indication: Keratinization disorders including pachyonychia congenita and other hyperkeratosis‑related skin diseases in adults and pediatric populations as appropriate Clinical stage: Early clinical development — Phase 1b proof‑of‑concept completed / ongoing exploration with potential Phase 2 plans and feasibility studies Modality: Small molecule (tyrosine kinase inhibitor) in topical form Mechanism / Target: Inhibitor of epidermal growth factor receptor (EGFR), aiming to reduce epidermal hyperproliferation and abnormal keratinization Route / form: Topical gel formulation designed for direct skin application Differentiation: First topical erlotinib formulation optimized for higher local concentration with minimal systemic exposure, intended to address rare hyperkeratosis conditions that lack approved targeted therapies